-
Giuseppe Curigliano on the Clinical Impact and Future of T-DXd Combo Therapy | CSCO 2025
The Current Cornerstone: The Historical Status and Limitations of the CLEOPATRA Regimen For over a decade, the first-line standard of care for HER2-positive metastatic breast cancer has been established by…
-
Owen O’Connor Provides an In-depth Analysis of the New Paradigm in T-cell Lymphoma Treatment | CSCO 2025
The 2025 Chinese Society of Clinical Oncology (CSCO) Annual Meeting was grandly held in the golden autumn season, gathering top experts from the global field of oncology. In the lymphoma session, the renowned American scholar, Professor Owen O’Connor, delivered a splendid presentation on the topic “REASONS FOR OPTIMISM IN TREATING THE T-CELL MALIGNANCIES: A BIOLOGICAL…
-
Summary Report of the International Workshop on Cell Therapy for Blood Diseases
The International Workshop on Cell Therapy for Blood Diseases, hosted by the Department of International Cooperation of the Ministry of Science and Technology of China, and organized by the Institute…
-
CSCO International Vision | Professors Zefei Jiang and Giuseppe Curigliano: CSCO x ESMO Join Forces to Build a United Front Against Cancer, Setting a Milestone with DB09 in HER2-Targeted Therapy
The 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan, Shandong, from September 10 to 14, 2025, under the theme “Standardized Treatment, Innovation-Driven Progress.” The meeting gathered leading scholars from China and abroad for a major exchange of ideas. In the field of breast cancer, Professor Giuseppe Curigliano, President-Elect…
Connecting Medical Expertise through Media